Year: 2007
Type: editorial
Abstract: In this issue of the Journal, 1 Home and colleagues report interim results from the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes, or RECORD, study (NCT00379769). The RECORD study is a 6-year, open-label, noninferiority trial in which patients with type 2 diabetes who had inadequate glucose control with metformin or sulfonylurea alone were randomly assigned to receive rosiglitazone (Avandia) or the combination of metformin and sulfonylurea. The primary outcome was a composite of hospitalization and death from cardiovascular causes. As of March 2007, data were available on the 4447 patients randomly assigned to receive one of these . . .
Source: New England Journal of Medicine
DOI: 10.1056/nejme078116
Authors: Bruce M. Psaty, Curt D. Furberg
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2006837571
